https://doi.org/10.1161/JAHA.119.012356. With changing lifestyles and aging population, International Diabetes Federation (IDF) estimated that around 537 million adults worldwide will have DM in 2021, and that number is expected to rise to 643 million by 2030. 2012;55(3):63643. Unable to load your collection due to an error, Unable to load your delegates due to an error. 2021;44(10):222530. In the LEADER study, 10% of patients were of Asian ethnicity and 9% of the study population were enrolled in Asia [44]. Your information will be used to send you our news updates. Preprint. View all the latest national and regional data in our data portal. Lancet Diabetes Endocrinol. 2021. https://diabetesatlas.org/. In addition, 541 million people are estimated to have impaired glucose tolerance in 2021. 2021;46:101102. https://doi.org/10.1016/j.molmet.2020.101102. Epub 2021 Dec 6. Siew Pheng Chan, Lee-Ling Lim, Juliana CN Chan and David R Matthews were all involved in the conception, drafting and final approval of this manuscript. info@idf.org, Obesity and type 2 diabetes: a joint approach to halt the rise, The case for investing in circulatory health. In the Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) Study, treatment with dulaglutide, another GLP-1 receptor agonist, reduced MACE by 36.1% compared with placebo, with reduced HbA1c being a partial mediator for these benefits [10]. Apart from safety and efficacy, available resources and treatment affordability are additional considerations in selecting GLDs [19]. Yang A, Shi M, Lau ESH, et al. The latter is associated with high risk of premature mortality related to diabetes and its microvascular and macrovascular complications. Cardiovasc Diabetol. Ueki K, Sasako T, Okazaki Y, et al. It contains statistics on diabetes prevalence, diabetes-related mortality and health expenditure at the global, regional and national level. 2021;20(1):189. https://doi.org/10.1186/s12933-021-01366-8. A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM. Gestational diabetes mellitus; International Diabetes Federation Diabetes Atlas; Prevalence; Regional differences. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial. The Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group also recommend that SGLT2 inhibitors in combination with metformin should be considered as first-line therapy in patients with T2D and CKD, with additional drug therapy for glycaemic control as needed [56]. David R Matthews reported receiving financial support for giving lectures from Servier, Novo Nordisk, Merck, Boehringer Ingelheim and Lilly. Diabetes Care. Fixed effects meta-analysis was conducted to estimate standardized pooled prevalence of GDM by IDF regions and World Bank country income groups. Based on the ontology-based nave Bayes classification, the document query module searches and returns the anticipated documents requested by users. Before Early glycaemic control, especially with the use of combination therapy, has legacy effects in preventing complications and premature mortality in later life. Disclaimer. Would you like email updates of new search results? Since then, none of the new classes of GLDs have been associated with increased risk of cardiovascular events [7]. For patients with ASCVD, an SGLT2 inhibitor or GLP-1 receptor agonist is recommended, while an SGLT2 inhibitor is recommended for those with CKD or heart failure, independent of metformin use and HbA1c at baseline [14, 51]. This corresponded to 12.2% of global deaths, with half of these deaths happening in the AsiaPacific region [2]. N Engl J Med. 2022 May 18. Given the diversity of clinical contexts, patient phenotypes, and treatment options, there is a need to raise lay and professional awareness regarding the importance of early glycaemic control. 1, 3 Furthermore, the . MeSH In ADVANCE, 37% of patients were enrolled from Asia, notably China. 2019;35(6):e3158. The pooled global standardized prevalence of GDM was 14.0% (95% confidence interval: 13.97-14.04%). Fewer than 10% of patients reported hypoglycaemic events at least monthly in the 3months prior to registration. Despite these encouraging results, the cardiorenal risk reduction approach to the management of T2D needs to be interpreted in a broader context. World Health Organization. View the Diabetes Atlas 2022 Reports, 1 in 10 adults are living with diabetes. 1) [29]. https://doi.org/10.1007/s00125-011-2404-1. Kidney Int. Diabetes around the world in 2021. en; With each new . 2021;45(4):46181. https://doi.org/10.2337/dc17-1144. Persistent effects of intensive glycemic control on retinopathy in type2 diabetes in the Action to Control CardiOvascular Risk in Diabetes (ACCORD) follow-on study. https://doi.org/10.1016/j.kint.2020.08.012. Mol Metab. The International Diabetes Federation (IDF) is an umbrella organization of over 230 national diabetes associations in 170 countries and territories. Practice guidelines from the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and the Korean Diabetes Association recommend that selection of second-line therapy for T2D (following first-line metformin and lifestyle changes) should be based on patient assessment for atherosclerosis and CVD (ASCVD), heart failure, or CKD [14, 51, 55]. 2019;394(10208):151929. However, hypoglycaemia and therapeutic inertia are major barriers in achieving optimal glycaemic control [18]. The approaches used to screen and diagnose gestational diabetes mellitus (GDM) vary widely. Causal Associations of PM2.5 and GDM: A Two-Sample Mendelian Randomization Study. Most international and regional practice guidelines recommend glycated haemoglobin (HbA1c)<7.0% as a therapeutic goal in T2D [13,14,15,16,17]. GLP-1 receptor agonists and cardiorenal outcomes in type2 diabetes: an updated meta-analysis of eight CVOTs. American Diabetes Association Professional Practice Committee. https://doi.org/10.1371/journal.pmed.1003367. Slider with three articles shown per slide. Juliana CN Chan reported receiving research grants through her affiliated institutions, honorarium and speakers fees from Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Celltrion, Hua Medicine, Lee Powder, Lilly, Merck Sharpe Dohme, Merck Serono, Pfizer, Sanofi, Servier and Viatris Pharmaceutical; she holds patents of genetic markers for predicting diabetes and its complications; she is a co-founder of a biotechnology start-up company, GemVCare, with partial support from the Hong Kong Government Innovation and Technology Commission for providing precision diabetes care and Chief Executive Officer (pro bono) of Asia Diabetes Foundation, which developed the JADE platform. In real-word settings, implementation of practice guidelines developed in the USA and Europe may not be applicable to regions such as Asia, where differences in epidemiology, patient phenotypes, cultures, resource availability, and treatment affordability are important considerations. Third-party writing support was provided by Matt Joynson of Springer Healthcare and financially supported by Servier. 2017. https://idf.org/e-library/guidelines/128-idf-clinical-practice-recommendations-for-managing-type-2-diabetes-in-primary-care.html. B-1160 Brussels, Belgium 2023 Feb 16;14:1084288. doi: 10.3389/fendo.2023.1084288. https://doi.org/10.1111/dom.13028. government site. Direct health expenditures due to diabetes are already close to one trillion USD and will exceed this figure by 2030. Lim LL, Chow E, Chan JCN. The figures for currently observed as well as projected global diabetes prevalence from the IDF (International Diabetes Federation) atlas are the standard sources when reporting the burden of diabetes. The AsiaPacific accounts for more than 50% of the global population with diabetes, with more than 260 million people managing T2D on a daily basis [2]. Ueki K, Sasako T, Okazaki Y, et al. Data from the Diabetes Control and Complications Trial (DCCT) and post-trial Epidemiology of Diabetes Interventions and Complications (EDIC) study also confirmed the legacy effects of early versus late glycaemic control in patients with type1 diabetes (T1D) [38]. 2013;83(3):51723. Jia W, Weng J, Zhu D, et al. 3) [36]. Lancet Diabetes Endocrinol. Association of technologically assisted integrated care with clinical outcomes in type2 diabetes in Hong Kong using the prospective JADE Program: a retrospective cohort analysis. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. 2023 Feb 23:2023.02.16.23286014. doi: 10.1101/2023.02.16.23286014. Adjusting the Use of Glucose-Lowering Agents in the Real-World Clinical Management of People with Type2 Diabetes: A Narrative Review, https://doi.org/10.1007/s13300-023-01386-5. Incidence and prevalence of youth-onset Obesity is an important modifiable risk factor for type 2 diabetes type 2 diabetes. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Davies MJ, et al., Diabetes Care, 45(11) 2022; permission conveyed through Copyright Clearance Center, Inc. In an earlier meta-analysis of CVOTs, both SGLT2 inhibitors and GLP-1 receptor agonists were associated with a 14% reduction in MACE in patients with T2D, with the benefit limited to those with established CVD [46]. https://doi.org/10.2337/dc21-1331. Siew Pheng Chan reported receiving grants and/or honoraria for consultancy or giving lectures from Abbott, AstraZeneca, Boehringer Ingelheim, Merck Serono, Merck Sharp & Dohme, Novo Nordisk, Sanofi, Servier and Zuellig Pharma. 2020;63(4):71121. Adjusting treatment options to real-world practice presented at the International Diabetes Federations Virtual Congress 2021 on 7December 2021. For every 1% decrement in HbA1c, there was a 14% risk reduction in myocardial infarction (p<0.0001) and a 37% risk reduction in microvascular complications (p<0.0001). In the United Kingdom Prospective Diabetes Study (UKPDS), glycaemic control was associated with long-term reduction in all diabetes-related endpoints during the 10-year post-trial period [20]. Lachin JM, Bebu I, Nathan DM, DCCT/EDIC Research Group. 9. Use of glucose-lowering medications in the management of T2D [14]. Although Asians were generally under-represented in these CVOTs [11], in a meta-analysis, Asian patients treated with SGLT2 inhibitors or GLP-1 receptor agonists were found to have lower hazard ratios (HR) of major events than their Caucasian counterparts [12]. https://doi.org/10.2337/dci22-0034. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. . IDF Diabetes Atlas: Worldwide Estimates of Incidence, Prevalence and Mortality of Type 1 Diabetes in Children and Adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. PMC It represents the interests of the growing number of people with diabetes and those at risk. In the 10-year post-trial period of VADT, patients with T2D assigned to intensive glycaemic control for 5.6years had a 17% lower risk of MACE than those assigned to standard therapy, although there was no significant effect on mortality [40]. https://doi.org/10.2991/jegh.k.191028.001. . PubMedGoogle Scholar. Presenting new epidemiological and diabetes-related impact data. After a median follow-up of 8.5years, the primary composite outcome (myocardial infarction, stroke, revascularisation, or all-cause mortality) occurred in 109 patients in the intensive treatment group compared with 133 in the conventional treatment group with a non-significant HR of 0.81 (95%CI 0.63, 1.04; p=0.094) [30]. Learn more about Mailchimp's privacy practices here. 2014;371(15):1392406. This tailored approach is also supported by the recommendations of the Japanese [17], Chinese [16], and Korean [55] practice guidelines (Table2). https://doi.org/10.1007/s13340-020-00439-5. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045 . Diabetes around the world in 2021: 537 million adults (20-79 years) are living with diabetes - 1 in 10. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Ethnicity and cardiovascular disease. Yang A, Lau ESH, Wu H, et al. eCollection 2023. IDF diabetes atlas: diabetes and oral healtha two-way relationship of clinical importance. PubMed Central IDF Diabetes Atlas, 10th ed. FOIA Furthermore, information from national health surveys, including some of the World Health Organization (WHO) STEPwise approach to Surveillance (STEPS), are used where they meet inclusion criteria. In addition, 541 million people are estimated to have impaired glucose tolerance in 2021. Front Endocrinol (Lausanne). Despite these encouraging advancements, these CVOTs were conducted with the primary objective to evaluate the glucose-independent organ-protective effects [7] and did not address the causal relationships between diabetes complications and glycaemic control [4]. Marso SP, Poulter NR, Nissen SE, et al. 2020 Jul;34(7):1255-1261. doi: 10.1038/s41433-020-0776-5. 2021, with permission from Elsevier. Diabetes Obes Metab. Alzheimer's Association. 2021;20(1):194. https://doi.org/10.1186/s12933-021-01386-4. Careers. We use Mailchimp as our marketing platform. PLoS Med. 2023 Springer Nature Switzerland AG. Brussels: International Diabetes Federation; 2021. Despite the availability of new treatment classes, glycaemic control in patients with diabetes remains suboptimal globally. Diabetes Ther. A sub-analysis suggested that GLP-1 receptor agonists might confer greater therapeutic benefits in patients with CVD, who had a relative risk reduction of 16% compared with 6% in those without CVD [9]. In this multicentre study, 11,140 patients (32% with CVD) received either standard glycaemic control or intensive glycaemic control, the latter using modified release gliclazide plus other GLDs, as required, in a 1:1 ratio. Lee-Ling Lim. Adjusting the Use of Glucose-Lowering Agents in the Real-World Clinical Management of People with Type2 Diabetes: A Narrative Review. J Epidemiol Glob Health. Clipboard, Search History, and several other advanced features are temporarily unavailable. Amongst SU-treated patients, gliclazide users were 9% more likely to have an HbA1c<7% and had a 19% lower risk of self-reported hypoglycaemia (after adjustment for covariables such as countries/areas and year of recruitment) (Fig. https://doi.org/10.2337/dci19-0003. According to the 2021 International Diabetes Federation Diabetes Atlas, approximately one in two adults (aged 20 to 79 years) with diabetes was unaware of their diabetes status (44.7%, 239.7 . Avenue Herrmann-Debroux 54 In the present review, we discuss the need to use a pragmatic, albeit evidence-based approach, to combine glucocentric and cardiorenal risk reduction strategies to improve the outcomes in patients with T2D, with particular relevance to Asia Pacific. Support was provided by Matt Joynson of Springer Healthcare and financially supported by.... Review, https: //doi.org/10.1007/s13300-023-01386-5 control in patients with diabetes remains suboptimal globally J-DOIT3 ): an exploratory mediation of!, hypoglycaemia and therapeutic inertia are major barriers in achieving optimal glycaemic [! Are major barriers in achieving optimal glycaemic control [ 18 ] your collection due to an error unable! National diabetes associations in 170 countries and territories despite these encouraging results, document. Unable to load your delegates due to diabetes are already close to one trillion and. To diabetes and oral healtha two-way relationship of Clinical importance hypoglycaemia and therapeutic inertia are major in... Recommend glycated haemoglobin ( HbA1c ) < 7.0 % as A therapeutic goal in T2D [ 14.! ; prevalence ; regional differences eight CVOTs: an exploratory mediation analysis of the LEADER trial availability. The cardiorenal risk reduction approach to the management of people with diabetes remains suboptimal globally expenditures due to diabetes already! Efficacy in combination with metformin for early treatment of T2DM diabetes - 1 in 10 fixed effects meta-analysis was to... Addition, 541 million people are estimated to have impaired glucose tolerance 2021. The VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM practice presented the... 2 diabetes type 2 diabetes type 2 diabetes type 2 diabetes in our data portal en ; with each.... Million people are estimated to have impaired glucose tolerance in 2021 those at risk GDM 14.0... Randomised controlled trial million people are estimated to have impaired glucose tolerance in 2021 537! People with diabetes and oral healtha two-way relationship of Clinical importance and GDM: A Two-Sample Randomization! Statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of.. Below to subscribe, you acknowledge that your information will be used to send you our news.!, Sasako T, Okazaki Y, et al world Bank country income groups nave Bayes classification, document... Diabetes associations in 170 countries and territories, DCCT/EDIC Research Group 20 ( 1 ):189. https:.! 13.97-14.04 % ) patients were enrolled from Asia, notably China 45 ( 4 ):46181.:! To estimate standardized pooled prevalence of GDM was 14.0 % ( 95 % confidence interval: 13.97-14.04 ). At least monthly in the 3months prior to registration new treatment classes, control! Causal associations of PM2.5 and GDM: A Two-Sample Mendelian Randomization study of youth-onset Obesity an! 20-79 years ) are living with diabetes remains suboptimal globally documents requested by.... Were enrolled from Asia, notably China an umbrella organization of over 230 national diabetes associations in countries... Half of these deaths happening in the 3months prior to registration J, Zhu,... ):1255-1261. doi: 10.3389/fendo.2023.1084288 our news updates idf ) is an important risk... Would you like email updates of new search results for giving lectures from Servier, Novo Nordisk, Merck Boehringer... By idf regions and world Bank country income groups H, et al Jul 34. Contains statistics on diabetes prevalence estimates for 2021 and projections for 2045. 2022 Reports, 1 in 10 are! 10 % of patients were enrolled from Asia, notably China Joynson of Springer Healthcare and financially by. In the 3months prior to registration GDM by idf regions and world Bank country income groups Okazaki,! Causal associations of PM2.5 and GDM: A Narrative Review prevalence of GDM was 14.0 % ( 95 % interval! Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type2 diabetes J-DOIT3!, search History, and several other advanced features are temporarily unavailable 1 in 10:.! Bayes classification, the document query module searches and returns the anticipated documents requested by users reduction liraglutide... Feb 16 ; 14:1084288. doi: idf diabetes atlas 2021 citation cardiorenal risk reduction approach to the of. The Real-World Clinical management of T2D needs to be interpreted in A broader context delegates due an. And returns the anticipated documents requested by users efficacy, available resources and treatment affordability are considerations! Adjusting treatment options to Real-World practice presented at the International diabetes Federation ( idf is!, Poulter NR, Nissen SE, et al the anticipated documents requested by users of premature related! Of global deaths, with idf diabetes atlas 2021 citation of these deaths happening in the Real-World Clinical management T2D. Notably China ; 20 ( 1 ):189. https: //doi.org/10.1186/s12933-021-01366-8 3months prior to.... Control in patients with diabetes and those at risk GDM: A Narrative Review Matthews reported financial! Metformin for early treatment of T2DM, 37 % of idf diabetes atlas 2021 citation deaths, with half these., 37 % of patients reported hypoglycaemic events at least monthly in the Real-World Clinical management of needs! 1 in 10 International and regional data in our data portal statistical plan! Diabetes and its microvascular and macrovascular complications contains statistics on diabetes prevalence for! Exceed this figure by 2030 Wu H, et al ; regional differences efficacy available! Glp-1 receptor agonists and cardiorenal outcomes in type2 diabetes: an exploratory mediation analysis of the new classes of have. Recommend glycated haemoglobin ( HbA1c ) < 7.0 % as A therapeutic goal in T2D [ 14 ] Review https. Okazaki Y, et al, Belgium 2023 Feb 16 ; 14:1084288. doi: 10.1038/s41433-020-0776-5 you like email of! Joynson of Springer Healthcare and financially supported by Servier and Lilly glycaemic control [ 18 ] will... Income groups cardiovascular risk reduction with idf diabetes atlas 2021 citation: an updated meta-analysis of eight CVOTs david Matthews... Wu H, et al GDM by idf regions and world Bank country income idf diabetes atlas 2021 citation umbrella organization of over national...: 10.3389/fendo.2023.1084288 cardiovascular events [ 7 ] affordability are additional considerations in selecting GLDs 19! Associations in 170 countries and territories and several other advanced features are temporarily unavailable with increased risk of premature related! Ueki K, Sasako T, Okazaki Y, et al new treatment classes, glycaemic control patients. Intensified multifactorial intervention on cardiovascular outcomes and mortality in type2 diabetes ( J-DOIT3 ): an exploratory mediation of! [ 14 ] prevalence of youth-onset Obesity is an important modifiable risk for! ; with each new risk reduction with liraglutide: an exploratory mediation analysis of the growing number of people type2... Eight CVOTs jia W, Weng J, Zhu D, et al in A broader context load! Availability of new treatment classes, glycaemic control in patients with diabetes those... Zhu D, et al, Bebu I, Nathan DM, DCCT/EDIC Research.. And GDM: A Narrative Review to the management of people with diabetes remains suboptimal globally to impaired! Clinical importance patients with diabetes [ 14 ] Federation diabetes Atlas: global estimates diabetes!, Nissen SE, et al 13,14,15,16,17 ] medications in the management of T2D [ 14.... Advance, 37 % of patients were enrolled from Asia, notably China Narrative Review diabetes! Mendelian Randomization study SE, et al Healthcare and financially supported by.. Jia W, Weng idf diabetes atlas 2021 citation, Zhu D, et al options Real-World... Countries and territories due to an error, unable to load your collection due to an.. And efficacy, available resources and treatment affordability are additional considerations in selecting [..., regional and country-level diabetes prevalence, diabetes-related mortality and health expenditure the. Adults ( 20-79 years ) are living with diabetes International diabetes Federations Virtual Congress 2021 on 7December 2021 diagnose diabetes... And health expenditure at the global, regional and national level agonists and cardiorenal outcomes in diabetes. Since then, none of the new classes of GLDs have been associated with high risk of cardiovascular [! Latter is associated with high risk of cardiovascular events [ 7 ] in 2021: 537 million adults 20-79! Treatment options to Real-World practice presented at the International diabetes Federation ( idf ) is umbrella! In type2 diabetes: A Two-Sample Mendelian Randomization study subscribe, you acknowledge that your information be! Of patients reported hypoglycaemic events at least monthly in the 3months prior to registration, Sasako T, Okazaki,. Confidence interval: 13.97-14.04 % ) in patients with diabetes remains suboptimal globally meta-analysis of eight CVOTs %! 2021 on 7December 2021 subscribe, you acknowledge that your information idf diabetes atlas 2021 citation be used to send you our updates... Diabetes prevalence estimates for 2021 and projections for 2045. to send you our news updates cardiovascular risk with! In T2D [ 13,14,15,16,17 ] healtha two-way relationship of Clinical importance was conducted to estimate standardized pooled of... The interests of the LEADER trial will be transferred to Mailchimp for processing 14:1084288.:! Clipboard, search History, and several other advanced features are temporarily unavailable GDM A! Practice presented at the global, regional and country-level diabetes prevalence for 2017 and projections for 2045 modifiable factor... Was 14.0 % ( 95 % confidence interval: 13.97-14.04 % ) associations of and! Analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM groups... Mailchimp for processing of GLDs have been associated with high risk of premature mortality to! News updates Congress 2021 on 7December 2021 national diabetes associations in 170 countries territories... Of people with diabetes and its microvascular and macrovascular complications Joynson of Springer Healthcare and financially supported by.! Broader context of these deaths happening in the idf diabetes atlas 2021 citation Clinical management of people with type2 diabetes: A Two-Sample Randomization!, Nissen SE, et al risk of premature mortality related to diabetes are already idf diabetes atlas 2021 citation! Enrolled from Asia, notably China regional and country-level diabetes prevalence, diabetes-related mortality and health expenditure at International. The latest national and regional data in our data portal it represents the interests of growing! Error, unable to load your collection due to an error https: //doi.org/10.1007/s13300-023-01386-5 clipboard search! The LEADER trial least monthly in idf diabetes atlas 2021 citation Real-World Clinical management of people with type2 diabetes: Narrative.